Abstract

Rationale

COVID-19 ARDS could differ from typical forms of the syndrome.

Objective

Pulmonary microvascular injury and thrombosis are increasingly reported as constitutive features of COVID-19 respiratory failure. Our aim was to study pulmonary mechanics and gas exchanges in COVID-2019 ARDS patients studied early after initiating protective invasive mechanical ventilation, seeking after corresponding pathophysiological and biological characteristics.

Methods

Between March 22 and March 30, 2020 respiratory mechanics, gas exchanges, circulating endothelial cells (CEC) as markers of endothelial damage, and D-dimers were studied in 22 moderate-to-severe COVID-19 ARDS patients, 1 [1–4] day after intubation (median [IQR]).

Measurements and main results

Thirteen moderate and 9 severe COVID-19 ARDS patients were studied after initiation of high PEEP protective mechanical ventilation. We observed moderately decreased respiratory system compliance: 39.5 [33.1–44.7] mL/cmH2O and end-expiratory lung volume: 2100 [1721–2434] mL. Gas exchanges were characterized by hypercapnia 55 [44–62] mmHg, high physiological dead-space (VD/VT): 75 [69–85.5] % and ventilatory ratio (VR): 2.9 [2.2–3.4]. VD/VT and VR were significantly correlated: r2 = 0.24, p = 0.014. No pulmonary embolism was suspected at the time of measurements. CECs and D-dimers were elevated as compared to normal values: 24 [12–46] cells per mL and 1483 [999–2217] ng/mL, respectively.

Conclusions

We observed early in the course of COVID-19 ARDS high VD/VT in association with biological markers of endothelial damage and thrombosis. High VD/VT can be explained by high PEEP settings and added instrumental dead space, with a possible associated role of COVID-19-triggered pulmonary microvascular endothelial damage and microthrombotic process.

Details

Title
Respiratory mechanics and gas exchanges in the early course of COVID-19 ARDS: a hypothesis-generating study
Author
Diehl J-L 1   VIAFID ORCID Logo  ; Peron, N 2 ; Chocron, R 3 ; Debuc, B 4 ; Guerot, E 2 ; Hauw-Berlemont, C 2 ; Hermann, B 2 ; Augy, J L 2 ; Younan, R 2 ; Novara, A 2 ; Langlais, J 2 ; Khider, L 5 ; Gendron, N 6 ; Goudot, G 7 ; J-F, Fagon 2 ; Mirault, T 8 ; Smadja, D M 6 

 Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France; AH-HP, Georges Pompidou European Hospital, Intensive Care Unit and Biosurgical Research Lab (Carpentier Foundation), Paris, France (GRID:grid.414093.b) 
 AH-HP, Georges Pompidou European Hospital, Université de Paris, Intensive Care Unit, Paris, France (GRID:grid.414093.b) 
 Université de Paris, PARCC, INSERM, Paris, France (GRID:grid.410511.0) (ISNI:0000 0001 2149 7878); AP–HP, Georges Pompidou European Hospital, Emergency Department, Paris, France (GRID:grid.414093.b) 
 AP-HP, Georges Pompidou European Hospital, Université de Paris, Plastic Surgery Department, Paris, France (GRID:grid.414093.b) 
 AP-HP, Georges Pompidou European Hospital, Université de Paris, Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Paris, France (GRID:grid.414093.b) 
 Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France (GRID:grid.414093.b); AH-HP, Georges Pompidou European Hospital, Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Paris, France (GRID:grid.414093.b) 
 AP–HP, Georges Pompidou European Hospital, Emergency Department, Paris, France (GRID:grid.414093.b) 
 Université de Paris, PARCC, INSERM, Paris, France (GRID:grid.410511.0) (ISNI:0000 0001 2149 7878); AP-HP, Georges Pompidou European Hospital, Vascular Medicine Department, Paris, France (GRID:grid.414093.b) 
Publication year
2020
Publication date
Dec 2020
Publisher
Springer Nature B.V.
e-ISSN
21105820
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2424342414
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.